NFE2L2 and familial pancreatic carcinoma: Brusatol, an inhibitor of Nrf2, has been demonstrated to abrogate gemcitabine-induced Nrf2 activation, increase ROS accumulation, and potentiate gemcitabine-induced growth inhibition and cytotoxicity in pancreatic cancer cells (181).